{"id":"W2133654917","doi":"10.1186/1756-8722-6-46","title":"A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)","year":2013,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Internal medicine; Sorafenib; Rash; Diffuse large B-cell lymphoma; Hematology; Lymphoma; Oncology; Progression-free survival; Neutropenia; Overall survival; Gastroenterology; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003429038,0.001254724,0.001838388,0.0003740625,0.0003362414,0.0005896357,0.0007112751,0.0007930298,0.001387042],"category_scores_gemma":[0.0009053546,0.0005822248,0.0009731324,0.0004222243,0.0008340513,0.0005037755,0.0003406355,0.002014779,0.0004059408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005836464,"about_ca_system_score_gemma":0.001469876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001022722,"about_ca_topic_score_gemma":0.002423156,"domain_scores_codex":[0.9991887,0.0005301564,0.00003400605,0.00008188361,0.00006737939,0.00009790255],"domain_scores_gemma":[0.999081,0.000132535,0.0001357922,0.00007477526,0.00005113952,0.0005247538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5956615,0.1307027,0.03779481,0.0008197381,0.002686113,0.0008376042,0.0007380462,0.004299366,0.09665289,0.0003076769,0.003692026,0.1258076],"study_design_scores_gemma":[0.529276,0.4282922,0.03336859,0.00001726388,0.0006260017,0.000441994,0.00007571209,0.001312472,0.004314225,0.0001306208,0.00211545,0.00002940161],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972662,0.0006258657,0.0002982157,0.0001322629,0.00002275295,0.0009805836,0.0002708948,0.00002436084,0.0003789589],"genre_scores_gemma":[0.992099,0.001192508,0.001909662,0.0004018278,0.00009445751,0.001600097,0.001635878,0.00001775187,0.001048776],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003429038,"threshold_uncertainty_score":0.01813471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02826236165496909,"score_gpt":0.3575336845043388,"score_spread":0.3292713228493697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}